Scientists discover new drug to improve life expectancy and quality for pancreatic cancer patients
A new drug which could improve life expectancy and quality for patients with hard-to-treat cancers, such as pancreatic cancer and relapsed breast cancer, has been invented by scientists at the University of Sheffield in the UK. The researchers founded the spin-out company Modulus Oncology, along with a team of experienced biotech entrepreneurs, to fast-track the drug into clinical testing within two years. The Sheffield team made the discovery after examining a hormone, called adrenomedullin, which controls blood pressure and other vital body processes, but also stimulates the growth and spread of cancer. Using novel drug molecules, known as adrenomedullin-2 receptor antagonists, the scientists discovered a way to block the way that adrenomedullin is used in communication with cancer cells, without affecting the way it helps to regulate vital processes in the body such as blood pressure.
Findings of the pioneering study, published in the journal ACS Pharmacology & Translational Science, show the new drug molecules have a positive effect in the treatment of pancreatic cancer in mouse models. Pancreatic cancer has the lowest survival rate of all common cancers, with only seven per cent of patients surviving five-years after diagnosis.
Professor Tim Skerry from the University of Sheffield's Department of Oncology and Metabolism and a team of academic and industrial scientists from a range of scientific disciplines have been working on the groundbreaking research for the past 12 years.
"The most extraordinary part of this new therapy is the fact that nature designed the hormone adrenomedullin to have two different types of receptor - one which helps to regulate our blood pressure and the other which is involved in the way that cancer cells communicate with each other and the host cells, helping cancers to grow and spread," said Professor Skerry.
"We have designed a unique piece to fit into nature's jigsaw which will block signals from one receptor but allow the other to work as normal. In blocking the hormone's communication with the cancer cells we are cutting off its supply to the things that it needs to thrive. This means tumours can't grow as fast as they are starved of the resources they need and it becomes more difficult for them to spread to other areas of the body," Skerry said.